DTaP vaccine


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to DTaP vaccine: Hib vaccine

DTaP vaccine

A preparation of diphtheria and tetanus toxoids and acellular pertussis proteins. It is used to immunize children against all three infections or adults at high risk of complications of infection with pertussis.
See also: vaccine
References in periodicals archive ?
A primary reason we immunize against pertussis as part of the DTaP vaccine beginning at 2 months of age is to induce immunity as quickly as possible.
Data are limited on the safety and immunogenicity of interchanging DTaP vaccines from different manufacturers (8).
The study was funded by Sanofi-Pasteur, maker of Daptacel DTaP vaccine.
Ways to create a better DTaP vaccine might involve incorporating a detoxified lipopolysaccharide or adding additional adjuvants to increase the innate immune response to the pertussis antigen.
The other candidate Tdap vaccine, Adacel, is nearly identical to Sanofi Pasteur's currently licensed DTaP vaccine, Daptacel, except that it contains lower levels of diphtheria toxoid and one of five pertussis antigens.
The large potential market for DTaP vaccines and other combination vaccines could provide substantial earnings and cash flow within the next two years.
Possible ways to create a better DTaP vaccine might involve incorporating a detoxified lipopolysaccharide or adding additional adjuvants to increase the innate immune response to the pertussis antigen.
Klein and her colleagues performed a case-control study using information in the Kaiser Permanente database on 277 patients aged 4-12 years who had received the full series of the DTaP vaccine but had nevertheless tested positive for pertussis between 2006 and 2011.
Several studies have suggested that maternal pertussis antibodies can inhibit active pertussis-specific antibody production after administration of DTaP vaccine to infants of mothers vaccinated with Tdap during pregnancy, referred to as blunting (12,17).
In a pivotal clinical study of 4,114 healthy 10-18 year olds, Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) was comparable in both immunogenicity and safety with a currently licensed tetanus-diphtheria toxoid(Td) vaccine and produced antibody responses at least as high as those seen in infants who receive the current higher-antigen DTaP vaccine, said Dr.
It appears that switching DtaP vaccine brands midstream has no affect on the child's antibody development and their ultimate protection from these childhood diseases.
This acellular pertussis vaccine has been combined with vaccines for the prevention of diphtheria and tetanus to formulate a unique DTaP vaccine, Certiva(TM).